摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-甲氧基-6-(甲基氨基)苯甲酸 | 254964-68-6

中文名称
2-甲氧基-6-(甲基氨基)苯甲酸
中文别名
他喹莫德中间体;2-甲氧基-6-(甲氨基)苯甲酸
英文名称
6-methoxy-N-methyl-anthranilic acid
英文别名
methyl 6-methoxyanthranilic acid;2-Methoxy-6-(methylamino)benzoic acid
2-甲氧基-6-(甲基氨基)苯甲酸化学式
CAS
254964-68-6
化学式
C9H11NO3
mdl
——
分子量
181.191
InChiKey
UUQSGGPDCDWBFV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    344.7±32.0 °C(Predicted)
  • 密度:
    1.245±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.2
  • 重原子数:
    13
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    58.6
  • 氢给体数:
    2
  • 氢受体数:
    4

安全信息

  • 储存条件:
    室温

SDS

SDS:2451ad2d0874012c039be6de823ef6c5
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Carboxy Group as a Remote and Selective Chelating Group for C−H Activation of Arenes
    作者:Shangda Li、Hang Wang、Yunxiang Weng、Gang Li
    DOI:10.1002/anie.201910691
    日期:2019.12.16
    The first example of carboxy group assisted, remote-selective C(sp2 )-H activation with a PdII catalyst has been developed and proceeds through a possible κ2 coordination of the carboxy group, thus suppressing the ortho-C-H activation through κ1 coordination. Besides meta-C-H olefination, direct meta-arylation of hydrocinnamic acid derivatives with low-cost aryl iodides has been achieved for the first
    已经开发了用PdII催化剂进行羧基辅助的远程选择性C(sp2)-H活化的第一个例子,并通过羧基的可能κ2配位进行,从而通过κ1配位抑制了邻位CH活化。除间位CH烯烃化外,首次实现了肉桂酸衍生物与低成本芳基碘化物的直接间芳基化。这些发现可能会激发人们对具有选择性的羧基辅助CH活化反应的新型反应性的探索。
  • Oxamic acid derivatives
    申请人:American Home Products Corporation
    公开号:US04154961A1
    公开(公告)日:1979-05-15
    Anti-allergic agents of aromatic oxamic acid derivation present the following formula: ##STR1## in which A is a member selected from the group consisting of .alpha.-naphthyl, .beta.-naphthyl, phenyl, 2,6-di-chlorophenyl, and substituted phenyl moieties containing from one to three substituents in any of the 2,3,4 and 5 positions of the phenyl ring, independently selected from the group consisting of lower alkyl, lower alkylthio, lower alkylsulfinyl, lower alkoxy, hydroxy (lower)alkoxy, 2-(oxalyloxy) ethoxy, benzyloxy, N-mono- and di-lower alkylamino(lower)alkoxy, halo, sulfamyl, polyhalo(lower)alkyl, carbamyl, N-lower alkylcarbamyl, nitro, mono and di lower alkylamino, carboxy, lower alkylcarbonyl, carb(lower)alkoxy, phenoxy(lower)alkoxy, and oxalamidophenoxy radicals; And pharmaceutically acceptable salts thereof.
    芳香族羧酸衍生物的抗过敏药物具有以下化学式:##STR1## 其中 A 是从以下组成的成员中选择的:α-萘基、β-萘基、苯基、2,6-二氯苯基和含有1至3个取代基的苯基基团,这些取代基可以独立地选择自以下组成的取代基:低烷基、低硫代烷基、低烷基磺基、低烷氧基、羟基(低)烷氧基、2-(草酰氧基)乙氧基、苄氧基、N-单-和双-低烷基氨基(低)烷氧基、卤素、磺酰胺基、多卤素(低)烷基、氨基甲酰基、N-低烷基氨基甲酰基、硝基、单和双低烷基氨基、羧基、低烷基羰基、氨基(低)羧基、苯氧基(低)烷氧基和草酰胺基苯氧基基团;以及其药用可接受的盐。
  • Pyridyl oxamic acid derivatives and use in the prevention of allergic
    申请人:American Home Products Corporation
    公开号:US04054661A1
    公开(公告)日:1977-10-18
    Anti-allergic agents of aromatic and heterocyclic oxamic acid derivation present the following formula: ##STR1## in which A is a member selected from the group consisting of 2-thiazolyl, 2-pyridyl, 2-pyridyl-N-oxide, 6-(lower)alkyl-2-pyridyl, 3-cyano-2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 2-pyrazinyl, .alpha.-naphthyl, .beta.naphthyl, phenyl, 2,6-dichlorophenyl, and substituted phenyl moieties containing from one to three substituents in any of the 2,3,4 and 5 positions of the phenyl ring, independently selected from the group consisting of lower alkyl, lower alkylthio, lower alkylsulfinyl, lower alkoxy, hydroxy(lower)-alkoxy, 2-(lower alkoxy oxalyloxy) ethoxy, benzyloxy, N-mono-and di-lower alkylamino(lower)-alkoxy, halo, sulfamyl, polyhalo(lower)alkyl, carbamyl, N-lower alkylcarbamyl, nitro, mono-and di-lower alkylamino, phenylazo, carboxy, lower alkylcarbonyl, cyano, carb(lower)alkoxy, phenoxy(lower)alkoxy, lower alkoxyoxalamido and lower alkoxyoxalamidophenoxy radicals; B, when taken alone, is a member selected from the group consisting of --OH, lower alkoxy, --NH.sub.2, --NHOH, cyclohexyloxy and phenoxy; and Y is a member selected from the group consisting of oxygen and when taken with B and the carbon atom to which they are attached, forms the moiety ##STR2##
    芳香族和杂环氧酰胺衍生的抗过敏剂具有以下公式:##STR1## 其中A是从2-噻唑基,2-吡啶基,2-吡啶基-N-氧化物,6-(较低)烷基-2-吡啶基,3-氰基-2-吡啶基,3-吡啶基,4-吡啶基,2-吡嘧啶基,2-吡嗪基,α-萘基,β-萘基,苯基,2,6-二氯苯基和取代苯基中选择的一种成员,所述取代苯基包含一个到三个取代基,所述取代基独立地选择自较低烷基,较低硫代烷基,较低磺代烷基,较低烷氧基,羟基(较低)-烷氧基,2-(较低烷氧基氧乙酰氧基)乙氧基,苄氧基,N-单和二-较低烷基氨基(较低)-烷氧基,卤,磺酰胺,多卤(较低)烷基,氨基甲酰,N-较低烷基氨基甲酰,硝基,单和二-较低烷基氨基,苯基偶氮,羧基,较低烷基羰基,氰基,羰基(较低)烷氧基,苯氧基(较低)烷氧基,较低烷氧基草酰胺基和较低烷氧基草酰胺基苯氧自由基;B,单独时,是从-OH,较低烷氧,-NH.sub.2,-NHOH,环己氧基和苯氧基中选择的一种成员;Y是从氧中选择的一种成员,当与B和它们连接的碳原子一起被选取时,形成如下部分:##STR2##
  • Oxamic acid derivatives for the prevention of immediate type
    申请人:American Home Products Corporation
    公开号:US03966965A1
    公开(公告)日:1976-06-29
    Anti-allergic agents of ##EQU1## and heterocyclic oxamic acid derivation present the following formula: IN WHICH A is a member selected from the group consisting of 2-thiazolyl, 2-pyridyl, 2-pyridyl-N-oxide, 6-(lower)alkyl-2-pyridyl, 3-cyano-2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 2-pyrazinyl, .alpha.-naphthyl, .beta.-naphthyl, phenyl, 2,6-dichlorophenyl, and substituted phenyl moieties containing from one to three substituents in any of the 2,3,4 and 5 positions of the phenyl ring, independently selected from the group consisting of lower alkyl, lower alkylthio, lower alkylsulfinyl, lower alkoxy, hydroxy(lower)-alkoxy, 2-(lower alkoxy oxalyloxy) ethoxy, benzyloxy, N-mono-and di-lower alkylamino(lower)-alkoxy, halo, sulfamyl, polyhalo(lower)alkyl, carbamyl, N-lower alkylcarbamyl, nitro, mono- and di-lower alkylamino, phenylazo, carboxy, lower alkylcarbonyl, cyano, carb(lower)alkoxy, phenoxy(lower)alkoxy, lower alkoxyoxalamido and lower alkoxyoxalamidophenoxy radicals; B, when taken alone, is a member selected from the group consisting of -OH, lower alkoxy, --NH.sub.2, --NHOH, cyclohexyloxy and phenoxy; and Y is a member selected from the group consisting of oxygen and when taken with B and the carbon atom to which they are attached, forms the moiety ##EQU2##
    ##EQU1##的抗过敏剂和杂环氧酰胺衍生物具有以下公式:其中A是从2-噻唑基,2-吡啶基,2-吡啶-N-氧化物,6-(较低)烷基-2-吡啶基,3-氰基-2-吡啶基,3-吡啶基,4-吡啶基,2-吡嘧啶基,2-吡啶基,α-萘基,β-萘基,苯基,2,6-二氯苯基和取代苯基等组成的群中选择的成员,其中该苯环的2,3,4和5位置中的任意位置都包含从一个到三个取代基的取代基,这些取代基独立地从较低烷基,较低硫代烷基,较低磺酰基,较低烷氧基,羟基(较低)-烷氧基,2-(较低烷氧基氧代羰基)乙氧基,苄氧基,N-单和二-较低烷基氨基(较低)-烷氧基,卤素,磺酰基,多卤代(较低)烷基,氨基甲酰基,N-较低烷基氨基甲酰基,硝基,单和双-较低烷基氨基,苯基偶氮基,羧基,较低烷基羰基,氰基,羰基(较低)烷氧基,苯氧基(较低)烷氧基,较低烷氧氧代草酰胺基和较低烷氧氧代草酰胺苯氧基自由基;B,当单独取时,是从-OH,较低烷氧基,-NH.sub.2,-NHOH,环己氧基和苯氧基等组成的群中选择的成员;Y是从氧中选择的成员,当与B和它们连接的碳原子一起取时,形成上述公式。
  • Quinoline derivatives
    申请人:Active Biotech AB
    公开号:US06133285A1
    公开(公告)日:2000-10-17
    The invention is related to compounds of general formula (I) wherein R is methyl, ethyl, n-propyl, iso-propyl, n-butyl or allyl; R' is methyl, methoxy, fluoro, chloro, bromo, trifluoromethyl, or OCH.sub.x F.sub.y, wherein x=0-2, y=1-3 with the proviso that x+y=3, R" is hydrogen, fluoro or chloro; with the proviso that R" is fluoro or chloro only when R' is fluoro or chloro; R.sub.4 is hydrogen or pharmaceutically acceptable inorganic or organic cations; R.sub.5 is ethyl, n-propyl, iso-propyl, methoxy, ethoxy, chloro, bromo, trifluoromethyl, OCH.sub.x F.sub.y, or OCH.sub.2 CH.sub.x F.sub.y wherein x=0-2, y=1-3 with the proviso that x+y=3; R.sub.6 is hydrogen; or R.sub.5 and R.sub.6 taken together are methylenedioxy; and any tautomer thereof. The invention also relates to pharmaceutical compositions containing a compound of the general formula (I) together with a pharmaceutically acceptable carrier. Included are also processes for the preparation of the compounds of formula (I), as well as methods for the treatment of mammals suffering from diseases resulting from autoimmunity and pathological inflammation by administering of a compound having the formula (I) to said mammal.
    该发明涉及一般式(I)的化合物,其中R为甲基、乙基、n-丙基、异丙基、n-丁基或烯丙基;R'为甲基、甲氧基、氟、氯、溴、三氟甲基或OCH.sub.x F.sub.y,其中x=0-2,y=1-3,但x+y=3;R"为氢、氟或氯;但R"仅当R'为氟或氯时为氟或氯;R.sub.4为氢或药用上可接受的无机或有机阳离子;R.sub.5为乙基、n-丙基、异丙基、甲氧基、乙氧基、氯、溴、三氟甲基、OCH.sub.x F.sub.y或OCH.sub.2 CH.sub.x F.sub.y,其中x=0-2,y=1-3,但x+y=3;R.sub.6为氢;或R.sub.5和R.sub.6一起为亚甲二氧基;以及其任何互变异构体。该发明还涉及含有一般式(I)的化合物的药物组合物,以及与药用可接受载体一起的。还包括一般式(I)化合物的制备方法,以及通过向患有自身免疫和病理性炎症疾病的哺乳动物施用具有一般式(I)的化合物来治疗的方法。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐